Skip to main content

Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

  • Book
  • © 2008

Overview

Part of the book series: Current Topics in Microbiology and Immunology (CT MICROBIOLOGY, volume 318)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

Keywords

About this book

"There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis."

Challenging Charcot’s hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.

Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement.

As internationally recognized specialists in a wide range of MS disciplines, the authors explore genetic tools for identifying patients who are most likely to experience spontaneous remyelination. Epidemiology studies offer additional avenues of treatment. Examples include uric acid, statin drugs, estrogen and progesterone.

MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science—and their applications in understanding cause and treatment—the authors offer help to clinicians and hope to patients.

Editors and Affiliations

  • Department of Neurology and Immunology, Mayo Clinic, College of Medicine, Rochester, USA

    Moses Rodriguez

Bibliographic Information

  • Book Title: Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

  • Editors: Moses Rodriguez

  • Series Title: Current Topics in Microbiology and Immunology

  • DOI: https://doi.org/10.1007/978-3-540-73677-6

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer-Verlag GmbH, DE, part of Springer Nature 2008

  • Hardcover ISBN: 978-3-540-73676-9Published: 05 December 2007

  • Softcover ISBN: 978-3-642-43783-0Published: 25 September 2014

  • eBook ISBN: 978-3-540-73677-6Published: 24 December 2007

  • Series ISSN: 0070-217X

  • Series E-ISSN: 2196-9965

  • Edition Number: 1

  • Number of Pages: XIV, 362

  • Topics: Neurology, Immunology

Publish with us